Does biopharma support the Califf nom for FDA? Yeah, whatever

Janet Woodcock, whose public legacy may now boil down to the approval of an unproven Alzheimer’s drug and whose industry legacy centers on putting the agency in sync with the largest drug developers, is set to step aside as Robert Califf makes his way back to the helm. And the industry largely appears to think that’s just fine.